Akums Drugs and Pharmaceuticals Limited reported its financial performance for the quarter and year ended March 31, 2026. The company achieved a consolidated annual revenue of ₹43,590.17 million and announced a total dividend of ₹3.00 per share, consisting of a ₹1.00 final dividend and a ₹2.00 special dividend. Additionally, the Board approved strategic management changes, including the appointment of a new President for HR to drive organizational growth.
Annual Financial Performance
For the financial year ended March 31, 2026, Akums Drugs and Pharmaceuticals Limited delivered robust results. The group reported consolidated annual revenue of ₹43,590.17 million, compared to ₹41,181.58 million in the previous year. The consolidated net profit for the year stood at ₹2,563.97 million, reflecting the company’s sustained operational focus in the pharmaceutical sector.
Dividend Recommendation
Demonstrating commitment to shareholder value, the Board has recommended a total dividend of ₹3.00 per equity share of ₹2 face value for the financial year 2025-26. This comprises a ₹1.00 final dividend (50%) and a ₹2.00 special dividend (100%). The company has fixed July 3, 2026, as the record date for determining eligibility, with payment subject to approval at the 22nd Annual General Meeting scheduled for July 10, 2026.
Leadership Updates
The company announced key changes to its Senior Management personnel effective May 14, 2026. Mr. V Jagannathan has been appointed as the new President – HR, bringing over 24 years of vast industry experience to the leadership team. He succeeds Mr. Arvind Srivastava, who is stepping down due to internal structural changes.
Operational Highlights
The company continues to advance its growth strategy, with the IPO proceeds being utilized efficiently across its core objectives. As of March 31, 2026, the company has successfully allocated funds toward the repayment of borrowings and the advancement of its inorganic growth initiatives. Additionally, the company is continuing to cooperate with the Income Tax Department regarding ongoing proceedings from the previous year, with management expressing confidence that no material adjustments to the financial results are required.
Source: BSE
